To assess the robustness of the IMLCI under alternative outcome specifications, a sensitivity analysis was performed using the original laboratory-inclusive definition of severe IBD, which incorporated CRP, WBC, ALT/AST, and albumin thresholds. This evidence concerns the gene ALB and inflammatory bowel disease.